Trial · NCT03181503
Results by group242
Each measurement the trial posted, group by group, in the words and numbers it posted.
81 to 100 of 242
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 8 | -0.7 | Standard Deviation 0.74 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 8 | -1.8 | Standard Deviation 1.06 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 12 | -0.7 | Standard Deviation 0.83 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 12 | -1.8 | Standard Deviation 1.09 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 16 | -0.7 | Standard Deviation 0.78 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 16 | -1.8 | Standard Deviation 1.16 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 18 | -0.8 | Standard Deviation 0.77 | Units on a scale |
| Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 18 | -1.7 | Standard Deviation 1.26 | Units on a scale |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 1 | -10.5 | Standard Deviation 19.72 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 1 | -29.6 | Standard Deviation 16.90 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 2 | -13.0 | Standard Deviation 19.20 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 2 | -42.9 | Standard Deviation 24.22 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 4 | -16.4 | Standard Deviation 24.10 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 4 | -52.1 | Standard Deviation 27.63 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 8 | -23.5 | Standard Deviation 22.89 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 8 | -55.4 | Standard Deviation 30.63 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 12 | -21.9 | Standard Deviation 25.90 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 12 | -62.1 | Standard Deviation 29.98 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Placebo | Week 16 | -25.1 | Standard Deviation 24.15 | percent change |
| Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach | Nemolizumab 0.5 mg/kg | Week 16 | -62.0 | Standard Deviation 32.48 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03181503/results?page=5